Could a lower dose of antibiotics be safer and just as effective for this lung infection?
NCT ID NCT04851015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a weakened immune system who have a serious lung infection called PCP. The standard treatment often causes bad side effects. Researchers want to see if a lower dose of the antibiotic TMP-SMX works just as well but with fewer side effects. About 416 adults will take part, and the study will compare the lower dose to the standard dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITINGMontreal, Quebec, H4A3J1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New score could help doctors spot fungal pneumonia faster
- Could a simple swab replace a lung scope for pneumocystis diagnosis?
- Could a shorter steroid course be just as good for HIV-Related pneumonia?
- New drug could shield transplant patients from deadly fungal infections
- New study seeks best backup plan for deadly pneumonia in immunocompromised patients
- Blood test may speed up deadly fungal infection diagnosis